Immunoglobulin administration can transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps and rubella. The immunizing physician should be informed of recent therapy with Vivaglobin®, Immune Globulin Subcutaneous (Human), so that appropriate precautions can be taken.
Vivaglobin® should not be mixed with other medicinal products.
As with all immune globulin products, Vivaglobin®, Immune Globulin Subcutaneous (Human) is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A (IgA) deficiency (serum IgA < 0.05 g/L) who have known antibody against IgA.
- Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1972;1:1208-12.
- Waniewski I, Gardulf A, Hammarström L. Bioavailability of γ-Globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994;14(2):90-7.
- Data on file.
- Roifmann CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobuli-naemia and chronic lung disease. Lancet 1987;1(8451):1075-7.
Revised: April 2007
Part number OBAH G46 00883 (18838A)
Package Label - Principal Display Panel - 10 × 3 mL
10 × 3 mL
Viva globin ®
Immune Globulin Subcutaneous (Human)
Ten Single Use Vials
Manufactured by: CSL Behring GmbH, 35041 Marburg, Germany
US License No. 1765
Package Label - Principal Display Panel - 10 mL
Viva globin ®
One Single Use Vial